PSA test

DIAGNOSTIC_TEST4 trials

Sponsors

Institute of Cancer Research, United Kingdom, Heinrich-Heine University, Duesseldorf, Albany Medical College, Peking University First Hospital

Conditions

BRCA MutationGenetic Predisposition to DiseaseMismatch Repair Gene MutationPSAProstate CancerProstate Inflammation

Phase 4

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

RecruitingNCT05629494

Albany Medical CollegeProstate Cancer, Prostate Inflammation, PSA

Start: 2022-09-27End: 2026-12-01Target: 198Updated: 2024-10-18

Unknown Phase

The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer

Active, not recruitingNCT00261456

Institute of Cancer Research, United KingdomBRCA Mutation, Genetic Predisposition to Disease, Mismatch Repair Gene Mutation +1

Start: 2005-03-31End: 2030-03-31Updated: 2025-09-26

Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance Imaging

Not yet recruitingNCT04993508

Heinrich-Heine University, DuesseldorfProstate Cancer

Start: 2026-04-01End: 2030-03-31Target: 1908Updated: 2025-09-26

Sequential bpMRI for Suspicious Prostate Lesions

Not yet recruitingNCT07332832

Peking University First HospitalProstate Cancer

Start: 2026-02-01End: 2029-05-31Target: 1000Updated: 2026-02-18

Related Papers

PRIMA: randomized prospective multicenter non-inferiority study for primary diagnosis of clinically significant PRostate cancer by PSA and MR IMAging—study protocol for a randomized diagnostic accuracy trial

Trials2026-04-25

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.

2021-10-1959 citations

Bringing Prostate Cancer Germline Genetics into Clinical Practice.

2019-07-0844 citations

Prostate-specific antigen velocity as a predictive biomarker in a prospective prostate cancer screening study (IMPACT study).

Journal of Clinical Oncology2015-03-01

Targeted prostate cancer screening in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers to detect clinically significant disease: Results from the initial screening round of the IMPACT study.

Journal of Clinical Oncology2014-02-011 citations